MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Clinical trials for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS trials appear
Sign up with your email to follow new studies for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for ulcerative colitis: drug trial targets chinese patients
Disease control Recruiting nowThis study tests a drug called vedolizumab in Chinese adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. About 402 participants will receive either the drug or a placebo to see if it reduces sym…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for kids with severe colitis: drug trial seeks remission
Disease control Recruiting nowThis study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can safely reduce symptoms and lead to remission at 12 and 52 weeks. Participants must have tried other t…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for ulcerative colitis sufferers?
Disease control Recruiting nowThis study tests a new drug called RO7790121 for people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. About 350 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goa…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 14, 2026 12:04 UTC